Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
Report
Real-time Quote. Real-time Tradegate - 10/23 08:15:04 am
61.593 EUR   +0.18%
10/20 UCB FIRST NINE :  Strong 9 …
10/20 UCB : By the time you finish reading this headline another person &h..
10/17UCB SA : quaterly earnings release
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
59.9(c) 61.26(c) 60.64(c) 60.07(c) 61.48(c) Last
270 425 493 515 253 424 301 306 706 641 Volume
-0.58% +2.27% -1.01% -0.94% +2.35% Change
More quotes
Financials (€)
Sales 2017 4 337 M
EBIT 2017 971 M
Net income 2017 614 M
Debt 2017 580 M
Yield 2017 1,95%
Sales 2018 4 523 M
EBIT 2018 1 097 M
Net income 2018 722 M
Debt 2018 72,3 M
Yield 2018 2,08%
P/E ratio 2017 18,02
P/E ratio 2018 15,53
EV / Sales2017 2,89x
EV / Sales2018 2,66x
Capitalization 11 958 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.The company was founded by Emmanuel Janssen on January 18, 1928 and is... 
Sector
Pharmaceuticals
Calendar
11/15Presentation
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
10/20 UCB FIRST NINE MONTHS INTERIM REPORT :  Strong 9 …
10/20 UCB : By the time you finish reading this headline another person …
10/17UCB SA : quaterly earnings release
10/17 UCB : Transparency notification The Capital Group Companies
10/13 UCB : Transparency notification The Capital Group Companies
09/21 UCB : Studies from UCB S.A. Reveal New Findings on Extracellular Space (Quantita..
09/15 NEW INDICATION FOR BRIVIACT® (BRIVAR : UCB’s newest antiepileptic drug &he..
09/14 UCB : New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of..
09/11 UCB : EVENITYTM (romosozumab) ARCH Study Results Published in the New England &h..
09/08 UCB : highlights latest EVENITY™ (romosozumab) research at the American So..
More news
Sector news : Pharmaceuticals - NEC
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on UCB 
UCB - 10/06
After the accumulation, an upward acceleration ?
BUY
UCB - 08/09
Close to a key level on the weekly chart
BUY
More Strategies
Latest Tweets
10/20UCB : By the time you finish reading this headline another person …  
10/18@ SMIpharm: RT PharmaMKTnet: How Wearable technologies can create behavioural.. 
10/18How Wearable technologies can create behavioural changes for patients with UC..
2
10/11BRIEF-?Partners Connected Health and UCB announce epilepsy partnership?  
10/10UCB downgraded by Zacks Investment Research to hold.  
More tweets
Qtime:49
News from SeekingAlpha
07/31 UCB's (UCBJF) CEO Jean Tellier on Q2 2017 Results - Earnings Call Transcript
07/17 FDA rejects Amgen's marketing application for osteoporosis candidate romosozu..
05/22 Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but..
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 65,8 €
Spread / Average Target 7,0%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB0.94%14 090
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223